Role of targeted therapy in the treatment of HER-2-positive breast cancer brain metastases
Brain metastases are detectable in 25-35 % of patients with progressive HER-2-positve breast cancer. Even after spreading metastases into the brain, chemotherapy in combination with anti-HER- 2 therapy improves survival due to better control of the systemic disease. The paper presents the results of...
Saved in:
Main Authors: | G. A. Dashyan (Author), V. F. Semiglazov (Author), P. V. Krivorot'ko (Author), T. Yu. Semiglazova (Author), E. E. Topuzov (Author), R. M. Paltuev (Author), K. Yu. Zernov (Author), V. S. Apollonova (Author), S. S. Ereshchenko (Author), A. V. Petrova (Author), E. K. Zhil'tsova (Author), O. A. Ivanova (Author) |
---|---|
Format: | Book |
Published: |
ABV-press,
2016-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
New prospects in the use of Kadcyla® in breast cancer
by: G. A. Dashyan, et al.
Published: (2015) -
Current approaches to the treatment of HER2‑positive breast cancer with brain metastases
by: T. Yu. Semiglazova, et al.
Published: (2021) -
Correlation of the value of sonoelastography strain ratio with the degree of pathological regression in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy
by: E. A. Bus'ko, et al.
Published: (2017) -
General St. Gallen-2015 guidelines for the treatment of early breast cancer (adapted by the experts of the Russian Society of Breast Oncologists)
by: V. F. Semiglazov, et al.
Published: (2015) -
COMPARATIVE ANALYSIS OF DIFFERENT NEOADJUVANT CHEMOTHERAPY REGIMENS FOR TRIPLE-NEGATIVE BREAST CANCER
by: P. V. Krivorotko, et al.
Published: (2017)